Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

PRV-002

Other · developed by Odyssey Group International

Phase 1 Most advanced trial (none active)
ODTX Developer
1 Registered trials

What is PRV-002?

PRV-002 is an investigational drug studied in Traumatic Brain Injury (TBI).

At a glance

Also known as
Experimental drug
Drug type
Other
Therapy area
Neurology
Developer
Odyssey Group International, Inc. (ODTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05033444 Phase 1 Traumatic Brain Injury (TBI) Completed ODTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Traumatic Brain Injury (TBI)

More from Odyssey Group International

OD-07656 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ODTX page.

Follow ODTX, the company behind PRV-002

See ODTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ODTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.